Health Equity and Clinical Research

  It's okay to fail. In fact, failure can be a valuable learning experience. But it's important to know when to cut our losses and move on to something else. "Success is not final, failure is not fatal: it is the courage to continue that counts."  - Winston Churchill

    Diversity in Clinical Trials: A Strategic and Economic Game-Changer? Editorial by Brian J. Stowell "We are not makers of history. We are made by history."  - Dr. Martin Luther King Jr. Introduction In the evolving landscape of clinical trials, supplier and patient diversity programs are no longer seen as merely ethical or compliance requirements—they are strategic imperatives. They enhance the overall efficacy of clinical trials, influence competitive differentiation, and contribute to economic growth. This article will unravel how these diversity programs can provide a strategic advantage, deliver measurable economic benefits, and, most importantly, improve health outcomes for diverse patient populations. Supplier Diversity Programs Supplier diversity programs encourage the inclusion of diverse suppliers, such as minority-owned, women-owned, and small businesses, in the procurement process for clinical trials. Not only does this lead to a more innovative and resilient su

 

Each individual must take part in diminishing the influence of social determinants on health. What steps can one take to create a positive impact? #socialdeterminantsofhealth   #SDoH   #empowerment   #healthcare